Protalix BioTherapeutics Analyst Ratings
Protalix BioTherapeutics Analyst Ratings
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a maintained with a price target of $7.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.45, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 589.66% | HC Wainwright & Co. | $7 → $10 | Maintains | Buy |
| 05/03/2021 | 382.76% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 06/08/2020 | 658.62% | HC Wainwright & Co. | $3 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月31日 | 589.66% | HC Wainwright公司 | $7→$10 | 維護 | 買 |
| 05/03/2021 | 382.76% | HC Wainwright公司 | $11→$7 | 維護 | 買 |
| 06/08/2020 | 658.62% | HC Wainwright公司 | $3→$11 | 維護 | 買 |
What is the target price for Protalix BioTherapeutics (PLX)?
Protalix BioTreateutics(PLX)的目標價格是多少？
The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on October 31, 2023. The analyst firm set a price target for $10.00 expecting PLX to rise to within 12 months (a possible 589.66% upside). 1 analyst firms have reported ratings in the last year.
2023年10月31日，HC Wainwright&Co.報道了Protalix BioTreatetics(美國證券交易所代碼：PLX)的最新目標價。這家分析公司將目標價定為10美元，預計PLX將在12個月內上漲至(可能上漲589.66)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Protalix BioTherapeutics (PLX)?
Protalix BioTreateutics(PLX)的最新分析師評級是多少？
The latest analyst rating for Protalix BioTherapeutics (AMEX: PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics maintained their buy rating.
對Protalix BioTreateutics(美國證券交易所市場代碼：PLX)的最新分析師評級由HC Wainwright&Co.提供，Protalix BioTreateutics維持其買入評級。
When is the next analyst rating going to be posted or updated for Protalix BioTherapeutics (PLX)?
Protalix BioTreeutics(PLX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Protalix BioTreateutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Protalix BioTreeutics的上一次評級是在2023年10月31日提交的，所以你應該預計下一次評級將在2024年10月31日左右提供。
Is the Analyst Rating Protalix BioTherapeutics (PLX) correct?
分析師對Protalix BioTreateutics(PLX)的評級正確嗎？
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a maintained with a price target of $7.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.45, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Protalix BioTreateutics(PLX)評級保持不變，目標價在7.00美元至10.00美元之間。Protalix BioTreateutics(PLX)目前的交易價格為1.45美元，超出了分析師的預測範圍。
